WHAT'S BEHIND MVASI®
MAKES THE DIFFERENCE

AMGEN® experience in biologics and science is behind all our products. The Amgen® bevacizumab providing you confidence and continuity.[1-3*†]

MVASI® is a bevacizumab biosimilar indicated for the treatment of: • Metastatic carcinoma of the colon or rectum in combination with fluoropyrimidine-based chemotherapy. • Metastatic breast cancer in combination with paclitaxel for first-line treatment. • Unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology, for first-line treatment in addition to platinum-based chemotherapy. • Advanced and/or metastatic renal cell cancer for first line treatment in combination with interferon alfa-2a. • Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer for front-line treatment in combination with carboplatin and paclitaxel. • First recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel for patients who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. • Platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with topotecan or pegylated liposomal doxorubicin for patients who have received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. • Persistent, recurrent, or metastatic carcinoma of the cervix in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy.

MVASI® (bevacizumab) injection 100mg/vial & 400mg/vial

*MVASI® has been approved as a biosimilar of AVASTIN® and is dosed and administered in the same way.
†The MVASI® therapeutic indications do not include the following uses:
· in combination with capecitabine for patients with breast cancer
· in combination with paclitaxel for patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
· in combination with erlotinib for patients with non-small cell lung cancer with EGFR activating mutations

AMGEN®

▣ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions

1. MVASI® (bevacizumab) prescribing information. June 2018; **2.** AVASTIN® (bevacizumab) Prescribing Information. June 2019; **3.** Amgen® Inc. Annual Report, Form 10-K 2018. Available at: https://www.sec.gov/Archives/edgar/data/318154/000031815419000008/amgn-12312018x10kq42018.htm. Accessed 24 February 2020.

MVASI®: THE AMGEN® BEVACIZUMAB THAT GIVES YOU CONFIDENCE AND CONTINUITY OF CARE[1,2]

Brought to you using AMGEN® IN-HOUSE development & manufacturing facilities[1,3,4]

FOR SAME TUMOUR TYPES AS AVASTIN® APPROVED



MVASI® CAN NOW BE USED FOR YOUR BEVACIZUMAB-ELIGIBLE PATIENTS AND IS APPROVED FOR USE IN THE SAME WAY AS THE REFERENCED PRODUCT[2*†]

- Same tumour types[1,2†]
- Highly similar efficacy and safety profile[1,2,5]
- Same pharmaceutical composition, including excipients and pH[1,2,5]

AMGEN® EXPERIENCE IN BIOLOGICS AND SCIENCE IS BEHIND MVASI®

40 YEARS OF EXPERIENCE IN BIOTECHNOLOGY[6]

HERITAGE IN SOLID TUMOURS[7-10]

MVASI® BACKED BY COMPREHENSIVE EVIDENCE FOR BIOEQUIVALENCE TO AVASTIN®[2,5]

DEDICATED PRESENCE & SUPPORT FROM AMGEN®[11]

*MVASI® has been approved as a biosimilar of AVASTIN® and is dosed and administered in the same way.
†The MVASI® therapeutic indications do not include the following uses:
· in combination with capecitabine for patients with breast cancer
· in combination with paclitaxel for patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
· in combination with erlotinib for patients with non-small cell lung cancer with EGFR activating mutations

1. MVASI® (bevacizumab) prescribing information. June 2018; **2.** AVASTIN® (bevacizumab) Prescribing Information. June 2019; **3.** Amgen® Inc. Annual Report, Form 10-K 2018. Available at: https://www.sec.gov/Archives/edgar/data/318154/000031815419000008/amgn-12312018x10kq42018.htm. Accessed 24 February 2020; **4.** Data on file; **5.** EMA. Committee for Medicinal Products for Human Use (CHMP). MVASI Assessment Report, EMA/798844/2017. Nov 2017; **6.** Amgen® website. Available at: https://www.amgen.com/science/. Accessed 24 February 2020; **7.** Aranesp® (darbepoetin alfa) prescribing information. Sep 2015; **8.** Vectibix® (panitumumab) prescribing information. Sep 2019; **9.** XGEVA® (denosumab) prescribing information; **10.** KANJINTI® (trastuzumab) prescribing information. Sep 2018; **11.** Amgen® solution-oriented services. Available at: https://www.amgenbiosimilars.com/support/solution-oriented-services/. Accessed 24 February 2020.

Amgen GmBH Limited, P.O. BOX7561, Riyadah, Al Olaya, Office 1102, Centeria Mall-4th floor, Riyadah 12242, Saudi Arabia
February 2020. PR-MVA-SAU-000014-01-2022

AMGEN®